Navigating the Global Clinical Landscape: CTA or IND for Your First-in-Human Study?
Worldwide Clinical Trials
MARCH 7, 2024
The two regulatory frameworks offer distinct benefits and disadvantages, but which one is right for your drug development program? Once the CTA is submitted, the EU requires a new CTA for any new protocols amended. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.
Let's personalize your content